Skip to main content
. 2021 Jul 25;17(12):3211–3223. doi: 10.7150/ijbs.62752

Figure 4.

Figure 4

Trametinib synergizes with rapamycin to induce cycle arrest of NSCLC cells in the G1-phase. (A) A549, PC9 and H1650 cells were treated with 50 nM rapamycin alone, or 50 nM trametinib alone, or in combination for 48 hours, and the cell cycle distribution was measured by flow cytometry. (B) Western blots of CDK2 and CDK4 in NSCLC cells treated with 50 nM rapamycin alone, or 50 nM trametinib alone, or in combination for 48 hours. Representative data were shown from three independent replicates. Error bars represent mean ± SD, **P < 0.01. vs control, ##P < 0.01. vs rapamycin or trametinib alone.